J&J Unit Revises Label For Evra Patch In Canada

Law360, New York (March 23, 2009, 12:00 AM EDT) -- Johnson & Johnson's Canadian subsidiary has updated labeling information for Evra, a birth control patch linked to blood clots, to state that the drug releases a greater amount of hormones on a daily basis than previously indicated.

Toronto-based Janssen-Ortho Inc. announced Thursday through Health Canada, the country's health care regulator, that it was changing the average daily release rates listed for the patch from 150 micrograms of norelgestromin, a progestin hormone, to 200 micrograms.

The figure listed for the amount of ethinyl estradiol, an estrogen hormone,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.